TCF-1 is a promising target to improve T cell–based HIV therapies because animal models suggest that TCF-1–regulated stem-like properties are essential for protective CD8+ T cell secondary recall responses after natural infection or vaccination (31, 35) and the survival of CD8+ T cells that experience chronic stimulation (37, 38). The gene discussed is CD8A; the disease is infection.